Sharyn Baker

Sharyn Baker

Sharyn Baker, PharmD, PhD

Gertrude Parker Heer Chair in Cancer Research,
Secondary Title
Professor and Chair
Unit / Department / Division
Pharmaceutics and Pharmacology
Outcomes and Translational Sciences Affiliated Faculty
Email Address
Phone Number

Professional Interests

Professional Interests

Dr. Baker’s cancer-relevant research interests broadly cover translational and clinical pharmacology of anti-cancer agents. Recently, her laboratory has focused on the preclinical development of anti-cancer agents for the treatment of acute myeloid leukemia (AML), with an emphasis on tyrosine kinase inhibitor (TKI) drug combinations. Dr. Baker’s research interests include developmental therapeutics for AML, clinical pharmacology of tyrosine kinase inhibitors, variability in anti-cancer drug disposition and investigational anti-cancer drug development.


  • 2004, Ph.D., Erasmus University Rotterdam, Medicine
  • 1991, Pharm.D., University of California, San Francisco, Pharmacy
  • 1986, B.A., Pacific Lutheran University, Biology
  • California State Board of Pharmacy No. 40219 (inac, California State Board of Pharmacy


  • Clinical and Translational Science Award, 2017

Journal Articles

Eisenmann ED, Talebi Z, Sparreboom A, Baker SD. Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions. Basic Clin Pharmacol Toxicol. 2021 Jun 12. doi: 10.1111/bcpt.13623. Epub ahead of print. PMID: 34117715. 

 Huang KM, Zavorka Thomas M, Magdy T, Eisenmann ED, Uddin ME, DiGiacomo DF, Pan A, Keiser M, Otter M, Xia SH, Li Y, Jin Y, Fu Q, Gibson AA, Bonilla IM, Carnes CA, Corps KN, Coppola V, Smith SA, Addison D, Nies AT, Bundschuh R, Chen T, Lustberg MB, Wang J, Oswald S, Campbell MJ, Yan PS, Baker SD, Hu S, Burridge PW, Sparreboom A. Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Proc Natl Acad Sci U S A. 2021 Feb 2;118(5):e2020168118. doi: 10.1073/pnas.2020168118. PMID: 33495337; PMCID: PMC7865186. 

Buelow DR, Anderson JT, Pounds SB, Shi L, Lamba JK, Hu S, Gibson AA, Goodwin EA, Sparreboom A, Baker SD. DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia. Clin Transl Sci. 2021 Jan;14(1):137-142. doi: 10.1111/cts.12861. Epub 2020 Sep 9. PMID: 32905646; PMCID: PMC7877866. 

 Jeon JY, Buelow DR, Garrison DA, Niu M, Eisenmann ED, Huang KM, Zavorka Thomas ME, Weber RH, Whatcott CJ, Warner SL, Orwick SJ, Carmichael B, Stahl E, Brinton LT, Lapalombella R, Blachly JS, Hertlein E, Byrd JC, Bhatnagar B, Baker SD. TP-0903 is active in models of drug-resistant acute myeloid leukemia. JCI Insight. 2020 Dec 3;5(23):e140169. doi: 10.1172/jci.insight.140169. PMID: 33268594; PMCID: PMC7714403. 

 Elsayed AH, Rafiee R, Cao X, Raimondi S, Downing JR, Ribeiro R, Fan Y, Gruber TA, Baker S, Klco J, Rubnitz JE, Pounds S, Lamba JK. Correction: A six- gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. Leukemia. 2020 Oct;34(10):2821. doi: 10.1038/s41375-020-0822-0. Erratum for: Leukemia. 2020 Mar;34(3):735-745. PMID: 32300185. 

 Garrison DA, Talebi Z, Eisenmann ED, Sparreboom A, Baker SD. Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors. Pharmaceutics. 2020 Sep 9;12(9):856. doi: 10.3390/pharmaceutics12090856. PMID: 32916864; PMCID: PMC7559291. 

 Eisenmann ED, Jin Y, Weber RH, Sparreboom A, Baker SD. Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Sep 1;1152:122176. doi: 10.1016/j.jchromb.2020.122176. Epub 2020 May 20. PMID: 32534260. 

 Hussaarts KGAM, van Doorn L, Eechoute K, Damman J, Fu Q, van Doorn N, Eisenmann ED, Gibson AA, Oomen-de Hoop E, de Bruijn P, Baker SD, Koolen SLW, van Gelder T, van Leeuwen RWF, Mathijssen RHJ, Sparreboom A, Bins S. Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib. Pharmaceutics. 2020 Aug 20;12(9):788. doi: 10.3390/pharmaceutics12090788. PMID: 32825359; PMCID: PMC7559746. 

 Chen M, Hu S, Li Y, Gibson AA, Fu Q, Baker SD, Sparreboom A. Role of Oatp2b1 in Drug Absorption and Drug-Drug Interactions. Drug Metab Dispos. 2020 May;48(5):419-425. doi: 10.1124/dmd.119.090316. Epub 2020 Feb 29. Erratum in: Drug Metab Dispos. 2020 Jun;48(6):446. PMID: 32114507; PMCID: PMC7180048. 

 Kim JY, Bai Y, Jayne LA, Hector RD, Persaud AK, Ong SS, Rojesh S, Raj R, Feng MJHH, Chung S, Cianciolo RE, Christman JW, Campbell MJ, Gardner DS, Baker SD, Sparreboom A, Govindarajan R, Singh H, Chen T, Poi M, Susztak K, Cobb SR, Pabla NS. A kinome-wide screen identifies a CDKL5-SOX9 regulatory axis in epithelial cell death and kidney injury. Nat Commun. 2020 Apr 21;11(1):1924. doi: 10.1038/s41467-020-15638-6. PMID: 32317630; PMCID: PMC7174303.